Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis

Oct. 20, 2021 12:00 UTC


- IMM-BCP-01 is a cocktail of three antibodies that target unique regions of the spike protein, including highly conserved epitopes.

 -The cocktail exhibits potent anti-viral activity against multiple SARS-CoV-2 isolates, including current and former CDC variants of concern, Delta, Alpha, Beta, and Gamma


EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The manuscript is concurrently undergoing scientific peer review for potential publication.

IMM-BCP-01 contains three monoclonal, antibodies that bind to non-overlapping regions of the spike protein, including highly conserved epitopes. In preclinical testing, the antibodies exhibit combinatorial effects against multiple SARS-CoV-2 strains, including CDC variants of concern, and significantly reduces viral load in the lungs of hamsters infected with a SARS-CoV-2 reference strain.

Immunome’s preclinical research demonstrates:

  • The three antibodies, derived from human immune response, bind to the spike protein in a non-competitive manner.
    • The first antibody binds to a sub-dominant epitope of the spike protein, which appears to be broadly conserved across all current and former SARS-CoV-2 variants of concern as well as other Betacoronaviruses and SARS-COV-1.
    • The second antibody is also directed at a broadly conserved epitope and exhibits an avidity-based binding mechanism.
    • The third antibody binds to a composite epitope involving the receptor binding ridge and an area adjacent to the receptor binding loop.
  • As a cocktail, the three antibodies demonstrate enhanced anti-viral activity.
    • Efficacious in pseudovirus neutralization against the CDC variant of concern, Delta.
    • Shows equal or better activity against live virus in the reference and the variants tested to-date (Alpha, Beta and Gamma).
    • Potent activation of phagocytosis and complement fixation – known to be critical for in vivo treatment efficacy
  • In both treatment and prophylactic settings, at corresponding doses of up to 9 mg/kg, the cocktail potently reduced live viral titers by approximately 3.2 - 4 logs (or up to 10,000-fold) in the lungs of Syrian hamsters infected with SARS-CoV-2 virus
  • Published data2 for Sotrovimab (GSK and VIR Biotechnology), at 30 mg/kg, the highest dose tested in the prophylactic setting, show approximately a 2 log (or 100-fold) reduction in live viral titer in the lungs of Syrian hamsters infected with SARS-COV-2

“SARS-CoV-2 and its emerging variants continue to be a major ongoing public health concern,” said Susan R. Weiss, Ph.D., Professor and Vice Chair of the Department of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, Co-Director at the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and a member of Immunome’s COVID-19 Advisory Board.1 “Evidence in the literature demonstrates that a combination of antibodies offers better protection than a single antibody and in addition a higher barrier to mutational drift. This factor must be carefully considered in the overall development of antibody therapeutics against this virus.”

“The potency and breadth of activity shown across multiple variants highlights the ability of our antibody cocktail to provide broad protection and potent viral load reduction in the widely used Syrian Hamster model. We believe that the three carefully selected antibodies, from the hundreds that we isolated, each provide unique antiviral properties and that, when combined as a cocktail in our research, these antibodies appear to mimic the natural human immune response,” said Purnanand Sarma, PhD, President & CEO of Immunome. “The preclinical efficacy of IMM-BCP-01 that we observed in Syrian hamsters infected with SARS-CoV-2 is promising and, if translated to humans, supports potential non-intravenous delivery.”

This study was funded by the U.S. Department of Defense (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), in collaboration with the Defense Health Agency (DHA).

  1. Weiss receives compensation as member of Immunome’s COVID-19 Advisory Board.
  2. Cathcart, A.L et al bioRxiv 2021.03.09.434607

About Immunome

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is on developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding Immunome’s beliefs and expectations regarding the advancement of its oncology and COVID-19 therapeutic antibody programs, execution of its clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM‐ONC‐01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “suggest,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions. Forward-looking statements are based on Immunome’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether the data will be published in a scientific journal and, if so, when and with what modifications; the uncertainties inherent in research and development, including Immunome’s ability to execute on its strategy including with respect to the timing of its R&D efforts, IND filings, initiation and completion of any clinical studies and other anticipated milestones; the effectiveness of Immunome’s antibody cocktail, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for selection of the cocktail; ; Immunome’s ability to fund operations; the competitive landscape and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome’s filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In this press release, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.


Immunome Contact
Corleen Roche
Chief Financial Officer
Immunome, Inc.

Investor Contact
Laurence Watts
Managing Director
Gilmartin, LLC


Source: Immunome, Inc.

Back to news